{
 "query": "mepolizumab",
 "ingredient": "mepolizumab",
 "slug": "mepolizumab",
 "rxcui": "1720597",
 "brands": [
  "Nucala"
 ],
 "names": [
  "mepolizumab"
 ],
 "classes": [],
 "alternatives": [],
 "label": {},
 "faers": {
  "total": 49423,
  "serious": 31141,
  "death": 3991,
  "hospitalization": 15965,
  "primary_suspect": 49417,
  "top_reactions": [
   [
    "Asthma",
    12771
   ],
   [
    "Dyspnoea",
    10579
   ],
   [
    "Wheezing",
    7132
   ],
   [
    "Product Dose Omission Issue",
    6636
   ],
   [
    "Cough",
    5100
   ],
   [
    "Therapeutic Product Effect Incomplete",
    5052
   ],
   [
    "Pneumonia",
    4645
   ],
   [
    "Drug Ineffective",
    4624
   ],
   [
    "Loss Of Personal Independence In Daily Activities",
    4242
   ],
   [
    "Sleep Disorder Due To A General Medical Condition",
    3118
   ],
   [
    "Fatigue",
    3078
   ],
   [
    "Off Label Use",
    3077
   ],
   [
    "Malaise",
    2776
   ],
   [
    "Condition Aggravated",
    2745
   ],
   [
    "Headache",
    2697
   ]
  ],
  "by_year": {
   "2019": 4618,
   "2020": 5679,
   "2021": 6096,
   "2022": 4726,
   "2023": 5643,
   "2024": 7763,
   "2025": 7633,
   "2026": 2085
  },
  "by_year_primary": {
   "2019": 4618,
   "2020": 5678,
   "2021": 6096,
   "2022": 4726,
   "2023": 5641,
   "2024": 7763,
   "2025": 7633,
   "2026": 2082
  }
 },
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "applications": 2,
  "nda": 0,
  "anda": 0,
  "first_approval": "20151104",
  "rems": false,
  "rems_last": "",
  "labeling_supplements": 0,
  "labeling_recent": 0,
  "sponsors": [
   "GLAXOSMITHKLINE",
   "GLAXOSMITHKLINE LLC"
  ],
  "unapproved": false,
  "first_approval_fmt": "11/04/2015"
 },
 "trials": {
  "total": 146,
  "completed": 77,
  "terminated": 6,
  "with_results": 53,
  "industry": 76,
  "phase3": 34,
  "results_share": 0.6883116883116883,
  "terminated_share": 0.0410958904109589
 },
 "pubmed": {
  "rct": 79,
  "meta": 28,
  "recent_rct": 37,
  "cochrane": [
   {
    "pmid": "26214266",
    "title": "Mepolizumab versus placebo for asthma",
    "year": "2015"
   }
  ]
 },
 "payments": {
  "year": "2024",
  "usd": 3882730.28,
  "records": 56910,
  "by_name": [
   [
    "Nucala",
    3882730.28
   ]
  ],
  "names_checked": [
   "mepolizumab",
   "Nucala"
  ],
  "source": "bulk-index"
 },
 "partd": {
  "year": "2024",
  "claims": 72258,
  "beneficiaries": 9062,
  "spend": 317907428.14,
  "by_brand": [
   {
    "brand": "Nucala",
    "claims": 72258,
    "per_claim": 4399.615657,
    "is_generic": false
   }
  ],
  "per_claim": 4399.61565695148
 },
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": {
  "listed": false,
  "status": "",
  "name": "",
  "matched": null,
  "stewardship": []
 },
 "exposure": null,
 "scores": {
  "safety": {
   "score": 100,
   "letter": "A",
   "why": [
    "Death share in reports is near or below the FAERS average (0.9x)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 65,
   "letter": "C",
   "why": [
    "79 randomized trials and 28 systematic reviews/meta-analyses indexed in PubMed",
    "1 independent Cochrane review(s) exist"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 100,
   "letter": "A",
   "why": [
    "No recalls on record since 2016"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 70,
   "letter": "C",
   "why": [
    "Pharma paid doctors $3,882,730 tied to this drug last year (-30)",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 40,
   "letter": "F",
   "why": [
    "No generic version approved: brand-only pricing (-30)",
    "No same-class alternatives found: little leverage to switch (-30)"
   ],
   "weight": 0.1
  }
 },
 "total": 81,
 "grade": "B",
 "questions": [
  "The most-reported problems in FDA's adverse event data are asthma, dyspnoea, wheezing, product dose omission issue. How would we recognize and handle those?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "The manufacturer pays physicians heavily to promote this drug. Have you received anything from them?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)"
 ]
}